作者
Elie Azoulay, Virginie Lemiale, Djamel Mokart, Saad Nseir, Laurent Argaud, Frédéric Pène, Loay Kontar, Fabrice Bruneel, Kada Klouche, François Barbier, Jean Reignier, Lilia Berrahil-Meksen, Guillaume Louis, Jean-Michel Constantin, Julien Mayaux, Florent Wallet, Achille Kouatchet, Vincent Peigne, Igor Théodose, Pierre Perez, Christophe Girault, Samir Jaber, Johanna Oziel, Martine Nyunga, Nicolas Terzi, Lila Bouadma, Christine Lebert, Alexandre Lautrette, Naike Bigé, Jean-Herlé Raphalen, Laurent Papazian, Michael Darmon, Sylvie Chevret, Alexandre Demoule
发表日期
2018/11/27
期刊
Jama
卷号
320
期号
20
页码范围
2099-2107
出版商
American Medical Association
简介
Importance
High-flow nasal oxygen therapy is increasingly used for acute hypoxemic respiratory failure (AHRF).
Objective
To determine whether high-flow oxygen therapy decreases mortality among immunocompromised patients with AHRF compared with standard oxygen therapy.
Design, Setting, and Participants
The HIGH randomized clinical trial enrolled 776 adult immunocompromised patients with AHRF (Pao2<60 mm Hg or Spo2<90% on room air, or tachypnea >30/min or labored breathing or respiratory distress, and need for oxygen ≥6 L/min) at 32 intensive care units (ICUs) in France between May 19, 2016, and December 31, 2017.
Interventions
Patients were randomized 1:1 to continuous high-flow oxygen therapy (n = 388) or to standard oxygen therapy (n = 388).
Main Outcomes and Measures
The primary outcome was day-28 mortality. Secondary outcomes included intubation and mechanical …
学术搜索中的文章
E Azoulay, V Lemiale, D Mokart, S Nseir, L Argaud… - Jama, 2018